{"podcast":{"title":"Decera Clinical Education Oncology Podcast","slug":"decera-clinical-education-oncology-podcast-1302999","podcast_index_feed_id":1302999,"rss_url":"https://feeds.simplecast.com/GlfUTtJq","website_url":"https://oncologypodcast.simplecast.com","image_url":"https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/2d9bf1a9-d5c4-4079-9b3e-a531bfcf7774/3000x3000/decera-onc-podcast-show-icon.jpg?aid=rss_feed","author":"Decera Clinical Education","episode_count":253,"summary":"Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.","last_synced_at":"2026-07-15T02:18:52.844818+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999"},"episode":{"title":"Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization","slug":"myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization","published_at":"2026-03-20T17:38:27+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization","show_page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999","url":"https://oncologypodcast.simplecast.com/episodes/myth-vs-medicine-pharmacists-perspective-on-adjuvant-cdk4-6-inhibitor-optimization-EWbEJ_1v","audio_url":"https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/8c96b42f-7480-42b6-83fb-4ddc615809d6/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=8c96b42f-7480-42b6-83fb-4ddc615809d6&feed=GlfUTtJq","summary":"Listen to oncology pharmacists, Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, discuss assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, providing their experiences using these therapies for their patients with early-stage breast cancer.","meta_description":"Listen to oncology pharmacists, Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, discuss assumptions about adjuvant CDK4/6 inhibitor u…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1511,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}